Patents Assigned to Cambridge Antibody Technology Limited
-
Patent number: 6806079Abstract: A member of a specific binding pair (sbp) is identified by expressing DNA encoding a genetically diverse population of such sbp members in recombinant host cells in which the sbp members are displayed in functional form at the surface of a secreted recombinant genetic display package (rgdp) containing DNA encoding the sbp member or a polypeptide component thereof, by virtue of the sbp member or a polypeptide component thereof being expressed as a fusion with a capsid component of the rgdp. The displayed sbps may be selected by affinity with a complementary sbp member, and the DNA recovered from selected rgdps for expression of the selected sbp members. Antibody sbp members may be thus obtained, with the different chains thereof expressed, one fused to the capsid component and the other in free form for association with the fusion partner polypeptide. A phagemid may be used as an expression vector, with said capsid fusion helping to package the phagemid DNA.Type: GrantFiled: November 28, 2000Date of Patent: October 19, 2004Assignees: Medical Research Council, Cambridge Antibody Technology LimitedInventors: John McCafferty, Anthony Richard Pope, Kevin Stuart Johnson, Henricus Renerus Jacobus Mattheus Hoogenboom, Andrew David Griffiths, Ronald Henry Jackson, Kaspar Philipp Holliger, James David Marks, Timothy Piers Clackson, David John Chiswell, Gregory Paul Winter, Timothy Peter Bonnert
-
Publication number: 20040157215Abstract: A member of a specific binding pair (sbp) is identified by expressing DNA encoding a genetically diverse population of such sbp members in recombinant host cells in which the sbp members are displayed in functional form at the surface of a secreted recombinant genetic display package (rgdp) containing DNA encoding the sbp member or a polypeptide component thereof, by virtue of the sbp member or a polypeptide component thereof being expressed as a fusion with a capsid component of the rgdp. The displayed sbps may be selected by affinity with a complementary sbp member, and the DNA recovered from selected rgdps for expression of the selected sbp members. Antibody sbp members may be thus obtained, with the different chains thereof expressed, one fused to the capsid component and the other in free form for association with the fusion partner polypeptide. A phagemid may be used as an expression vector, with said capsid fusion helping to package the phagemid DNA.Type: ApplicationFiled: March 18, 2004Publication date: August 12, 2004Applicants: Cambridge Antibody Technology Limited, Medical Research CouncilInventors: John McCafferty, Anthony Richard Pope, Kevin Stuart Johnson, Henricus Renerus Jacobus Mattheus Hoogenboom, Andrew David Griffiths, Ronald Henry Jackson, Kaspar Philipp Holliger, James David Marks, Timothy Piers Clackson, David John Chiswell, Gregory Paul Winter, Timothy Peter Bonnert
-
Publication number: 20040157214Abstract: A member of a specific binding pair (sbp) is identified by expressing DNA encoding a genetically diverse population of such sbp members in recombinant host cells in which the sbp members are displayed in functional form at the surface of a secreted recombinant genetic display package (rgdp) containing DNA encoding the sbp member or a polypeptide component thereof, by virtue of the sbp member or a polypeptide component thereof being expressed as a fusion with a capsid component of the rgdp. The displayed sbps may be selected by affinity with a complementary sbp member, and the DNA recovered from selected rgdps for expression of the selected sbp members. Antibody sbp members may be thus obtained, with the different chains thereof expressed, one fused to the capsid component and the other in free form for association with the fusion partner polypeptide. A phagemid may be used as an expression vector, with said capsid fusion helping to package the phagemid DNA.Type: ApplicationFiled: March 18, 2004Publication date: August 12, 2004Applicants: Cambridge Antibody Technology Limited, Medical Research CouncilInventors: John McCafferty, Anthony Richard Pope, Kevin Stuart Johnson, Henricus Renerus Jacobus Mattheus Hoogenboom, Andrew David Griffiths, Ronald Henry Jackson, Kaspar Philipp Holliger, James David Marks, Timothy Piers Clackson, David John Chiswell, Gregory Paul Winter, Timothy Peter Bonnert
-
Patent number: 6593081Abstract: Methods are disclosed for the production of human self-antibodies and antibody fragments, which bind human antigens. Methods comprise providing a library of replicable genetic display packages (rgdps), such as filamentous phage, each rgdp displaying at its surface a member of a specific binding pair which is an antibody or antibody fragment, and each rgdp containing nucleic acid sequence derived from a species of mammal. The nucleic acid sequence in each rgdp encodes a polypeptide chain which is a component part of the sbp member displayed at the surface of that rgdp. Human antibodies or antibody fragments are selected by binding with human antigens. The displayed antibody fragments may be scFv, Fd, Fab or any other fragment which has the capability of binding to and is a human antigen. Nucleic acid libraries used may be derived from V-gene sequences of unimmunised humans. Part or all of the nucleic acid may be derived from oligonucleotide synthesis.Type: GrantFiled: March 21, 2000Date of Patent: July 15, 2003Assignees: Medical Research Council, Cambridge Antibody Technology LimitedInventors: Andrew David Griffiths, Hendricus Renerus Jacobus Mattheus Hoogenboom, James David Marks, John McCafferty, Gregory Paul Winter, Geoffrey Walter Grigg
-
Patent number: 6582915Abstract: Methods are disclosed for the production of anti-self antibodies and antibody fragments, being antibodies or fragments of a particular species of mammal which bind self antigens of that species. Methods comprise providing a library of replicable genetic display packages (rgdps), such as filamentous phage, each rgdp displaying at its surface a member of a specific binding pair which is an antibody or antibody fragment, and each rgdp containing nucleic acid sequence derived from a species of mammal. The nucleic acid sequence in each rgdp encodes a polypeptide chain which is a component part of the sbp member displayed at the surface of that rgdp. Anti-self antibody fragments are selected by binding with a self antigen from the said species of mammal. The displayed antibody fragments may be scFv, Fd, Fab or any other fragment which has the capability of binding antigen. Nucleic acid libraries used may be derived from a rearranged V-gene sequences of unimmunised mammal.Type: GrantFiled: November 28, 2000Date of Patent: June 24, 2003Assignees: Medical Research Council, Cambridge Antibody Technology LimitedInventors: Andrew David Griffiths, Hendricus Renerus Jacobus Mattheus Hoogenboom, James David Marks, John McCafferty, Gregory Paul Winter, Geoffrey Walter Grigg
-
Patent number: 6555313Abstract: Methods are disclosed for the production of human self-antibodies and antibody fragments, which bind human antigens. Methods comprise providing a library of replicable genetic display packages (rgdps), such as filamentous phage, each rgdp displaying at its surface a member of a specific binding pair which is an antibody or antibody fragment, and each rgdp containing nucleic acid sequence derived from a species of mammal. The nucleic acid sequence in each rgdp encodes a polypeptide chain which is a component part of the sbp member displayed at the surface of that rgdp. Human antibodies or antibody fragments are selected by binding with human antigens. The displayed antibody fragments may be scFv, Fd, Fab or any other fragment which has the capability of binding to and is a human antigen. Nucleic acid libraries used may be derived from V-gene sequences of unimmunised humans. Part or all of the nucleic acid may be derived from oligonucleotide synthesis.Type: GrantFiled: May 16, 2000Date of Patent: April 29, 2003Assignees: Medical Research Council, Cambridge Antibody Technology LimitedInventors: Andrew David Griffiths, Hendricus Renerus Jacobus Mattheus Hoogenboom, James David Marks, John McCafferty, Gregory Paul Winter, Geoffrey Walter Grigg
-
Patent number: 6544731Abstract: Methods are disclosed for the production of anti-self antibodies and antibody fragments, being antibodies or fragments of a particular species of mammal which bind self antigens of that species. Methods comprise providing a library of replicable genetic display packages (rgdps), such as filamentous phage, each rgdp displaying at its surface a member of a specific binding pair which is an antibody or antibody fragment, and each rgdp containing nucleic acid sequence derived from a species of mammal. The nucleic acid sequence in each rgdp encodes a polypeptide chain which is a component part of the sbp member displayed at the surface of that rgdp. Anti-self antibody fragments are selected by binding with a self antigen from the said species of mammal. The displayed antibody fragments may be scFv, Fd, Fab or any other fragment which has the capability of binding antigen. Nucleic acid libraries used may be derived from a rearranged V-gene sequences of unimmunised mammal.Type: GrantFiled: November 20, 1998Date of Patent: April 8, 2003Assignees: Medical Research Council, Cambridge Antibody Technology LimitedInventors: Andrew David Griffiths, Hendricus Renerus Jacobus Mattheus Hoogenboom, James David Marks, John McCafferty, Gregory Paul Winter, Geoffrey Walter Grigg
-
Patent number: 6521404Abstract: Methods are disclosed for the production of anti-self antibodies and antibody fragments, being antibodies or fragments of a particular species of mammal which bind self antigens of that species. Methods comprise providing a library of replicable genetic display packages (rgdps), such as filamentous phage, each rgdp displaying at its surface a member of a specific binding pair which is an antibody or antibody fragment and each rgdp containing nucleic acid sequence derived from a species of mammal. The nucleic acid sequence in each rgdp encodes a polypeptide chain which is a component part of the sbp member displayed at the surface of that rgdp. Anti-self antibody fragments are selected by binding with a self antigen from the said species of mammal. The displayed antibody fragments may be scFv, Fd, Fab or any other fragment which has the capability of binding antigen. Nucleic acid libraries used may be derived from a rearranged V-gene sequences of unimmunised mammal.Type: GrantFiled: November 20, 1998Date of Patent: February 18, 2003Assignees: Medical Research Council, Cambridge Antibody Technology LimitedInventors: Andrew David Griffiths, Hendricus Renerus Jacobus Mattheus Hoogenboom, James David Marks, John McCafferty, Gregory Paul Winter, Geoffrey Walter Grigg
-
Patent number: 6492497Abstract: The invention provides specific binding members, for example in the form of antibody variable domains, based on the CDR3 sequences of the antibody VH regions of SL15 (SEQ ID NO:4) and JT182 (SEQ ID NO:10). The antibodies have strong neutralizing activity for TGF&bgr;1 and are useful in treating conditions associated with excess TGF&bgr;1 activity, such as fibrosis, immune responses and tumor progression.Type: GrantFiled: April 28, 2000Date of Patent: December 10, 2002Assignee: Cambridge Antibody Technology LimitedInventors: Julia Elizabeth Thompson, Simon Nicholas Lennard, Alison Jane Wilton, Peta Sally Helena Braddock, Sarah Leila Du Fou, John Gerald McCafferty, Louise Anne Conroy, Philip Ronald Tempest
-
Patent number: 6492160Abstract: Methods, recombinant host cells and kits are disclosed-for the production of members of specific binding pairs (sbp), e.g. antibodies, using display on the surface of secreted replicable genetic display packages (rgdps), e.g. filamentous phage. To produce a library of great diversity recombination occurs between first and second vectors comprising nucleic acid encoding first and second polypeptide chains of sbp members respectively, thereby producing recombinant vectors each encoding both a first and a second polypeptide chain component of a sbp member. The recombination may take place in vitro or intracellularly and may be site-specific, e.g. involving use of the loxP sequence and mutants thereof. Recombination may take place after prior screening or selecting for rgdps displaying sbp members which bind complementary sbp member of interest.Type: GrantFiled: June 25, 1998Date of Patent: December 10, 2002Assignees: Cambridge Antibody Technology Limited, Medical Research CouncilInventors: Andrew David Griffiths, Samuel Cameron Williams, Peter Michael Waterhouse, Ahuva Nissim, Gregory Paul Winter, Kevin Stuart Johnson, Andrew John Hammond Smith
-
Patent number: 6489123Abstract: A method of labelling molecules which includes providing in a common medium a label molecule, a marker ligand able to bind a member of a specific binding pair, such as an antigen, a sbp member, an enzyme able to catalyze binding of the label molecule to other molecules, the enzyme being associated with the marker ligand; causing or allowing binding of the marker ligand to the sbp member; and causing or allowing binding of the label molecule to other molecules in the vicinity of the marker ligand bound to the sbp member. The marker ligand may be an antibody or any specific binding molecule, such as a chemokine or cytokine. A complementary member of the specific binding pair may be included, e.g. an antibody, or a diverse population of such sbp members, e.g. antibodies, may be included within which those which bind the counterpart sbp member, e.g. antigen, may be labelled and subsequently isolated for manipulation and/or use.Type: GrantFiled: January 23, 2001Date of Patent: December 3, 2002Assignee: Cambridge Antibody Technology LimitedInventors: Jane Katharine Osbourn, Elaine Joy Derbyshire, John Gerald McCafferty, Tristan John Vaughan, Kevin Stuart Johnson
-
Patent number: 6342588Abstract: A method of labelling molecules which includes providing in a common medium a label molecule, a marker ligand able to bind a member of a specific binding pair, such as an antigen, a sbp member, an enzyme able to catalyse binding of the label molecule to other molecules, the enzyme being associated with the marker ligand; causing or allowing binding of the marker ligand to the sbp member; and causing or allowing binding of the label molecule to other molecules in the vicinity of the marker ligand bound to the sbp member. The marker ligand may be an antibody or any specific binding molecule, such as a chemokine or cytokine. A complementary member of the specific binding pair may be included, e.g. an antibody, or a diverse population of such sbp members, e.g. antibodies, may be included within which those which bind the counterpart sbp member, e.g. antigen, may be labelled and subsequently isolated for manipulation and/or use.Type: GrantFiled: August 16, 1999Date of Patent: January 29, 2002Assignee: Cambridge Antibody Technology LimitedInventors: Jane Katharine Osbourn, Elaine Joy Derbyshire, John Gerald McCafferty, Tristan John Vaughan, Kevin Stuart Johnson
-
Patent number: 6180336Abstract: A method of labelling molecules which includes providing in a common medium a label molecule, a marker ligand able to bind a member of a specific binding pair, such as an antigen, a sbp member, an enzyme able to catalyse binding of the label molecule to other molecules, the enzyme being associated with the marker ligand; causing or allowing binding of the marker ligand to the sbp member; and causing or allowing binding of the label molecule to other molecules in the vicinity of the marker ligand bound to the sbp member. The marker ligand may be an antibody or any specific binding molecule, such as a chemokine or cytokine. A complementary member of the specific binding pair may be included, e.g. an antibody, or a diverse population of such sbp members, e.g. antibodies, may be included within which those which bind the counterpart sbp member, e.g. antigen, may be labelled and subsequently isolated for manipulation and/or use.Type: GrantFiled: June 17, 1998Date of Patent: January 30, 2001Assignee: Cambridge Antibody Technology LimitedInventors: Jane Katharine Osbourn, Elaine Joy Derbyshire, John Gerald McCafferty, Tristan John Vaughan, Kevin Stuart Johnson
-
Patent number: 6172197Abstract: A member of a specific binding pair (sbp) is identified by expressing DNA encoding a genetically diverse population of such sbp members in recombinant host cells in which the sbp members are displayed in functional form at the surface of a secreted recombinant genetic display package (rgdp) containing DNA encoding the sbp member or a polypeptide component thereof, by virtue of the sbp member or a polypeptide component thereof being expressed as a fusion with a capsid component of the rgdp. The displayed sbps may be selected by affinity with a complementary sbp member, and the DNA recovered from selected rgdps for expression of the selected sbp members. Antibody sbp members may be thus obtained, with the different chains thereof expressed, one fused to the capsid component and the other in free form for association with the fusion partner polypeptide. A phagemid may be used as an expression vector, with said capsid fusion helping to package the phagemid DNA.Type: GrantFiled: June 7, 1995Date of Patent: January 9, 2001Assignees: Medical Research Council, Cambridge Antibody Technology LimitedInventors: John McCafferty, Anthony Richard Pope, Kevin Stuart Johnson, Henricus Renerus Jacobus Mattheus Hoogenboom, Andrew David Griffiths, Ronald Henry Jackson, Kaspar Philipp Holliger, James David Marks, Timothy Piers Clackson, David John Chiswell, Gregory Paul Winter, Timothy Peter Bonnert
-
Patent number: 5994519Abstract: A method of labelling molecules which includes providing in a common medium a label molecule, a marker ligand able to bind a member of a specific binding pair, such as an antigen, a sbp member, an enzyme able to catalyse binding of the label molecule to other molecules, the enzyme being associated with the marker ligand; causing or allowing binding of the marker ligand to the sbp member; and causing or allowing binding of the label molecule to other molecules in the vicinity of the marker ligand bound to the sbp member. The marker ligand may be an antibody or any specific binding molecule, such as a chemokine or cytokine. A complementary member of the specific binding pair may be included, e.g. an antibody, or a diverse population of such sbp members, e.g. antibodies, may be included within which those which bind the counterpart sbp member, e.g. antigen, may be labelled and subsequently isolated for manipulation and/or use.Type: GrantFiled: July 8, 1997Date of Patent: November 30, 1999Assignee: Cambridge Antibody Technology LimitedInventors: Jane Katharine Osbourn, Elaine Joy Derbyshire, John Gerald McCafferty, Tristan John Vaughan, Kevin Stuart Johnson
-
Patent number: 5977319Abstract: The invention relates to specific binding members for estradiol and materials and methods relating thereto, in particular antibodies or binding domains thereof which have high affinities (low dissociation constants) for estradiol and low cross-reactivity for other steroids. The invention further provides means to make such binding members, assay methods for the detection and/or quantitation of estradiol, and nucleic acid encoding said binding members, which nucleic acid may be used for their production. Preferred binding members include those with CDR regions of the D12 antibody heavy and light chain domains (SEQ ID NO:2 and SEQ ID NO:12 respectively).Type: GrantFiled: October 21, 1997Date of Patent: November 2, 1999Assignee: Cambridge Antibody Technology LimitedInventors: Anthony Richard Pope, Kevin Pritchard, Andrew James Williams, Kevin Stuart Johnson
-
Patent number: 5969108Abstract: A member of a specific binding pair (sbp) is identified by expressing DNA encoding a genetically diverse population of such sbp members in recombinant host cells in which the sbp members are displayed in functional form at the surface of a secreted recombinant genetic display package (rgdp) containing DNA encoding the sbp member or a polypeptide component thereof, by virtue of the sbp member or a polypeptide component thereof being expressed as a fusion with a capsid component of the rgdp. The displayed sbps may be selected by affinity with a complementary sbp member, and the DNA recovered from selected rgdps for expression of the selected sbp members. Antibody sbp members may be thus obtained, with the different chains thereof expressed, one fused to the capsid component and the other in free form for association with the fusion partner polypeptide. A phagemid may be used as an expression vector, with said capsid fusion helping to package the phagemid DNA.Type: GrantFiled: January 8, 1993Date of Patent: October 19, 1999Assignees: Medical Research Council, Cambridge Antibody Technology LimitedInventors: John McCafferty, Anthony Richard Pope, Kevin Stuart Johnson, Henricus Renerus Jacobus Mattheus Hoogenboom, Andrew David Griffiths, Ronald Henry Jackson, Kaspar Philipp Holliger, James David Marks, Timothy Piers Clackson, David John Chiswell, Gregory Paul Winter, Timothy Peter Bonnert
-
Patent number: 5962255Abstract: Methods, recombinant host cells and kits are disclosed for the production of members of specific binding pairs (sbp), e.g. antibodies, using display on the surface of secreted replicable genetic display packages (rgdps), e.g. filamentous phage. To produce a library of great diversity recombination occurs between first and second vectors comprising nucleic acid encoding first and second polypeptide chains of sbp members respectively, thereby producing recombinant vectors each encoding both a first and a second polypeptide chain component of a sbp member. The recombination may take place in vitro or intracellularly and may be site-specific, e.g. involving use of the loxP sequence and mutants thereof. Recombination may take place after prior screening or selecting for rgdps displaying sbp members which bind complementary sbp member of interest.Type: GrantFiled: December 5, 1994Date of Patent: October 5, 1999Assignees: Cambridge Antibody Technology Limited, Medical Research CouncilInventors: Andrew David Griffiths, Samuel Cameron Williams, Peter Michael Waterhouse, Ahuva Nissim, Gregory Paul Winter, Kevin Stuart Johnson, Andrew John Hammond Smith
-
Patent number: 5885793Abstract: Methods are disclosed for the production of anti-self antibodies and antibody fragments, being antibodies or fragments of a particular species of mammal which bind self-antigens of that species. Methods comprise providing a library of replicable genetic display packages (rgdps), such as filamentous phage, each rgdp displaying at its surface a member of a specific binding pair which is an antibody or antibody fragment, and each rgdp containing nucleic acid sequence derived from a species of mammal. The nucleic acid sequence in each rgdp encodes a polypeptide chain which is a component part of the sbp member displayed at the surface of that rgdp. Anti-self antibody fragments are selected by binding with a self antigen from the said species of mammal. The displayed antibody fragments may be scFv, Fd, Fab or any other fragment which has the capability of binding antigen. Nucleic acid libraries used may be derived from a rearranged V-gene sequences of unimmunised mammal.Type: GrantFiled: October 26, 1994Date of Patent: March 23, 1999Assignees: Medical Research Council, Cambridge Antibody Technology LimitedInventors: Andrew David Griffiths, Hendricus Renerus Jacobus Mattheus Hoogenboom, James David Marks, John McCafferty, Gregory Paul Winter, Geoffrey Walter Grigg
-
Patent number: 5871907Abstract: The invention provides methods and kits for producing specific binding pairs (sbp) members. Populations of polypeptide chain components of sbp members are combined to form libraries of sbps displayed by secreted replicable genetic display packages (rgdp). At least one of the polypeptide chains is expressed as a fusion with a component of an rgdp which thereby displays that polypeptide chain at the surface of rgdp. At least one population of polypeptide chains is expressed from nucleic acid which is capable of being packaged using a component of an rgdp, whereby the genetic material of rgdps produced encodes a polypeptide chain. The methods enable production of libraries of multimeric sbp members from a very large number of possible combinations. In one embodiment of the invention a method employs "chain shuffling" in the production of sbp members of desired specificity for a counterpart sbp member. Selection procedures are also described.Type: GrantFiled: March 31, 1994Date of Patent: February 16, 1999Assignees: Medical Research Council, Cambridge Antibody Technology LimitedInventors: Gregory Paul Winter, Kevin Stuart Johnson, Andrew David Griffiths, Andrew John Hammond Smith